Special Issue "Marine Myxobacteria: Sea Secrets from the Slime"

A special issue of Marine Drugs (ISSN 1660-3397).

Deadline for manuscript submissions: closed (15 May 2018).

Special Issue Editors

Guest Editor
Dr. Jim La Clair E-Mail
Xenobe Research Institute, P.O. Box 3052, San Diego, CA, USA
Phone: 858-401-3083
Co-Guest Editor
Prof. Dr. Rolf Müller Website E-Mail
Department of Microbial Natural Products (MINS), Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Inhoffenstraße 7, 38124 Braunschweig, Germany
Interests: Molecular Biology; Biotechnology; Genetics; Biochemistry; Cancer Research; Analytical Chemistry; Bioengineering; Catalysis

Special Issue Information

Dear Colleagues:

Myxobacteria are one of the most robust producers of secondary metabolites. This special issue reports on the state-of-the-art in the discovery, evaluation and translation of myxobacterial metabolites. The issue will focus on topics related to: whole genome metabolite mining in myxobacteria; natural product biosynthesis in myxobacteria; elucidation of myxobacterial natural product scaffolds; elaboration and establishment of discrete modes of action; understanding of myxobacterial metabolite communication in nature; and, the role in which they play in ongoing and future clinical and commercial applications.

Dr. Jim La Clair
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • myxobacteria
  • polyketides
  • terpenes
  • peptides
  • alkaloids
  • natural products
  • secondary metabolites
  • drug discovery
  • modes of action
  • pharmaceuticals
  • agricultural agents
  • clinical trials

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Review

Open AccessReview
Metabolic and Biosynthetic Diversity in Marine Myxobacteria
Mar. Drugs 2018, 16(9), 314; https://doi.org/10.3390/md16090314 - 05 Sep 2018
Cited by 3
Abstract
Prior to 2005, the vast majority of characterized myxobacteria were obtained from terrestrial habitats. Since then, several species of halotolerant and even obligate marine myxobacteria have been described. Chemical analyses of extracts from these organisms have confirmed their ability to produce secondary metabolites [...] Read more.
Prior to 2005, the vast majority of characterized myxobacteria were obtained from terrestrial habitats. Since then, several species of halotolerant and even obligate marine myxobacteria have been described. Chemical analyses of extracts from these organisms have confirmed their ability to produce secondary metabolites with unique chemical scaffolds. Indeed, new genera of marine-derived myxobacteria, particularly Enhygromyxa, have been shown to produce novel chemical scaffolds that differ from those observed in soil myxobacteria. Further studies have shown that marine sponges and terrestrial myxobacteria are capable of producing similar or even identical secondary metabolites, suggesting that myxobacterial symbionts may have been the true producers. Recent in silico analysis of the genome sequences available from six marine myxobacteria disclosed a remarkably versatile biosynthetic potential. With access to ever-advancing tools for small molecule and genetic evaluation, these studies suggest a bright future for expeditions into this yet untapped resource for secondary metabolites. Full article
(This article belongs to the Special Issue Marine Myxobacteria: Sea Secrets from the Slime)
Show Figures

Figure 1

Open AccessReview
Future Directions of Marine Myxobacterial Natural Product Discovery Inferred from Metagenomics
Mar. Drugs 2018, 16(9), 303; https://doi.org/10.3390/md16090303 - 29 Aug 2018
Cited by 1
Abstract
Over the last two decades, halophilic (organisms that thrive at high salt concentrations) and halotolerant (organisms that have adapted to high salt concentrations) myxobacteria emerged as an important source of structurally diverse secondary metabolites from the marine environment. This review explores the advance [...] Read more.
Over the last two decades, halophilic (organisms that thrive at high salt concentrations) and halotolerant (organisms that have adapted to high salt concentrations) myxobacteria emerged as an important source of structurally diverse secondary metabolites from the marine environment. This review explores the advance of metagenomics analysis and 16S rRNA gene phylogeny of the cultured and uncultured myxobacteria from marine and other salt-environments up to July 2018. The diversity of novel groups of myxobacteria in these environments appears unprecedented, especially in the Sorangiineae and Nannocystineae suborders. The Sandaracinaceae related clade in the Sorangiineae suborder seems more widely distributed compared to the exclusively marine myxobacterial cluster. Some of the previously identified clones from metagenomic studies were found to be related to the Nannocystineae suborder. This understanding provides the foundation for a vital, unexplored resource. Understanding the conditions required to cultivate these yet “uncultured” myxobacteria in the laboratory, while a key next step, offers a significant potential to further expand access to diverse secondary metabolites. Full article
(This article belongs to the Special Issue Marine Myxobacteria: Sea Secrets from the Slime)
Show Figures

Figure 1

Back to TopTop